Skip to Main Content

Paper Details

Patient Out-of-Pocket Costs Following the Availability of Biosimilar Versions of Infliximab.
Clin Pharmacol Ther
5
2023
Author NameAffiliation
Aaron S KesselheimDivision of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital
Aaron S KesselheimHarvard Medical School
Aaron S KesselheimDivision of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital
  • 1 - 3

Datasets

Release 1.2